

SequenceListing

SEQUENCE LISTING

<110> Rensen, Patrick C.N.
 Havekes, Aloysius M.
 <120> Prevention, therapy and prognosis/monitoring in sepsis and septic shock
 <130> P59702U500 <140> US
 <141> 2004-12-22
 <150> PCT/NL03/00475
 <151> 2003-06-27
 <150> NL 1020962
 <151> 2002-06-28
 <160> 11
 <170> PatentIn version 3.1
 <210> 1
 <211> 17
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> human apoCI peptide
 <400> 1
 Met Arg Glu Trp Phe Ser Glu Thr Phe Gln Lys Val Lys Glu Lys Leu
 1 5 10 15
 Lys
 <210> 2
 <211> 57
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> human apoC1 peptide
 <400> 2
 Thr Pro Asp Val Ser Ser Ala Leu Asp Lys Leu Lys Glu Phe Gly Asn Thr
 1 5 10 15
 Leu Glu Asp Lys Ala Arg Glu Leu Ile Ser Arg Ile Lys Gln Ser Glu
 20 25 30
 Leu Ser Ala Lys Met Arg Glu Trp Phe Ser Glu Thr Phe Gln Lys Val
 35 40 45
 Lys Glu Lys Leu Lys Ile Asp Ser
 50 55
 <210> 3
 <211> 23
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> human apoC1 peptide

SequenceListing

<400> 3
Ser Ala Lys Met Arg Glu Trp Phe Ser Glu Thr Phe Gln Lys Val Lys
1 5 10 15

Glu Lys Leu Lys Ile Asp Ser
20

<210> 4
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> C-terminal part of human apoCI

<400> 4
Lys Val Lys Glu Lys Leu Lys
1 5

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> LPS-binding sequence of LALF

<400> 5
Lys Trp Lys Tyr Lys Gly Lys
1 5

<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> LPS-binding sequence of CAP18

<400> 6
Lys Ile Lys Glu Lys Leu Lys
1 5

<210> 7
<211> 57
<212> PRT
<213> Baboon

<220>
<221> SITE
<222> (1)..(57)
<223> primary amino acid sequence of apoCI

<400> 7
Ala Pro Asp Val Ser Ser Ala Leu Asp Lys Leu Lys Glu Phe Gly Asn
1 5 10 15

Thr Leu Glu Asp Lys Ala Trp Glu Val Ile Asn Arg Ile Lys Gln Ser
20 25 30

Glu Phe Pro Ala Lys Thr Arg Asp Trp Phe Ser Glu Thr Phe Arg Lys
35 40 45

SequenceListing

Val Lys Glu Lys Leu Lys Ile Asn Ser
50 55

<210> 8
<211> 61
<212> PRT
<213> Canis sp.

<220>
<221> SITE
<222> (1)..(61)
<223> primary amino acid sequence of apoCI

<400> 8
Ala Gly Glu Ile Ser Ser Thr Phe Glu Arg Ile Pro Asp Lys Leu Lys
1 5 10 15

Glu Phe Gly Asn Thr Leu Glu Asp Lys Ala Arg Ala Ala Ile Glu Ser
20 25 30

Ile Lys Lys Ser Asp Ile Pro Ala Lys Thr Arg Asn Trp Phe Ser Glu
35 40 45

Ala Phe Lys Val Lys Glu His Leu Lys Thr Ala Phe Ser
50 55 60

<210> 9
<211> 62
<212> PRT
<213> Rattus sp.

<220>
<221> SITE
<222> (1)..(62)
<223> primary amino acid sequence of apoC1

<400> 9
Ala Pro AS Phe Ser Ser Ala Met Glu Ser Leu Pro Asp Lys Leu Lys
1 5 10 15

Glu Phe Gly Asn Thr Leu Glu Asp Lys Ala Arg Ala Ala Ile Glu His
20 25 30

Ile Lys Gln Lys Glu Ile Met Ile Lys Thr Arg Asn Trp Phe Ser Glu
35 40 45

Thr Leu Asn Lys Met Lys Glu Lys Leu Lys Thr Thr Phe Ala
50 55 60

<210> 10
<211> 62
<212> PRT
<213> Mus sp.

<220>
<221> SITE
<222> (1)..(62)
<223> primary amino acid sequence of apoC1

<400> 10
Ala Pro Asp Leu Ser Gly Thr Leu Glu Ser Ile Pro Asp Lys Leu Lys
1 5 10 15

SequenceListing

Glu Phe Gly Asn Thr Leu Glu Asp Lys Ala Arg Ala Ala Ile Glu His
20 25 30

Ile Lys Gln Lys Glu Ile Leu Thr Lys Thr Arg Ala Trp Phe Ser Glu
35 40 45

Ala Phe Gly Lys Val Lys Glu Lys Leu Lys Thr Thr Phe Ser
50 55 60

<210> 11

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> human apoCI peptide

<400> 11

Met Arg Glu Trp Phe Ser Glu Thr Phe Gln Lys Val Lys Glu Lys
1 5 10 15

<210> 12

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> human apoCl peptide

<400> 12

Leu Ser Ala Lys Met Arg Glu Trp Phe Ser Glu Thr Phe Gln Lys Val
1 5 10 15

Lys Glu Lys Leu Lys Ile Asp Ser
20

<210> 13

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> human apoCl peptide

<400> 13

Thr Pro Asp Val Ser Ser Ala Leu Asp Lys Leu Lys Glu Phe Gly Asn
1 5 10 15

Thr Leu Glu Asp Lys Ala Arg Glu Leu Ile Ser Arg Ile Lys Gln Ser
20 25 30

Glu